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http://dx.doi.org/10.1016/j.ccr.2013.04.009SUMMARYMolecular programs that mediate normal cell differentiation are required for oncogenesis and tumor cell sur-
vival in certain cancers. How cell-lineage-restricted genes specifically influencemetastasis is poorly defined.
In lung cancers, we uncovered a transcriptional program that is preferentially associated with distal airway
epithelial differentiation and lung adenocarcinoma (ADC) progression. This program is regulated in part by
the lineage transcription factors GATA6 and HOPX. These factors can cooperatively limit the metastatic
competence of ADC cells, by modulating overlapping alveolar differentiation and invasogenic target genes.
Thus, GATA6 and HOPX are critical nodes in a lineage-selective pathway that directly links effectors of airway
epithelial specification to the inhibition of metastasis in the lung ADC subtype.INTRODUCTION
Aberrant activation of cell-lineage-restricted pathways is
required for oncogenic transformation in certain malignancies
(Garraway and Sellers, 2006). In contrast, the role of cell differen-
tiation programs in constraining tumor progression and metas-
tasis is poorly defined. Understanding how the molecular deter-
minants of cell fate affect metastasis is particularly relevant
in nonsmall cell lung cancers (NSCLC). NSCLC encompass
therapeutically intractable and biologically diverse subtypes of
tumors, including adenocarcinomas (ADC), squamous cell carci-
nomas (SCC), and large cell carcinomas (LCC) (Gabrielson,
2006). Each subtype harbors different genetic alterations,
exhibits unique histological features, and contains epithelial cells
of distinct lineages, portending major challenges in predicting
their clinical outcome.Significance
Lung adenocarcinoma (ADC) is a deadly and heterogeneous su
sion, the emergence of alternate cell lineage traits in primary t
anisms and biological consequences of these phenomena ar
identified two lineage transcription factors, GATA6 and HOPX
their expression in a subset of ADCs correlates with aberrant
eratively restrict the metastatic potential of ADC cells, by modu
lial differentiation and malignant invasion. Our findings demon
determinant of metastasis in specific lung cancers.Multipotent cells from the primary lung buds differentiate into
epithelial bronchiolar or alveolar progenitors of the proximal and
distal airway, respectively (Morrisey and Hogan, 2010). In post-
natal lungs, these cells may arise from regional stem cells in
the trachea or distal airways. Bronchiolar lineages include ciliated
and secretory cell types, whereas alveolar stem or progenitors
specify intoalveolar type I or type II pneumocytes that are required
for proper gas exchange. Lung epithelial differentiation is coordi-
nated by a complex network of transcription factors (TFs) whose
expression and activity are lineage specific (Maeda et al., 2007).
Significantly, SCC cells resemble proximal basal progenitors
of the trachea and bronchi (Eramo et al., 2010). Conversely,
ADCs form in the distal airways and can arise from alveolar
progenitors, including alveolar type II (AT2) cells (Xu et al.,
2012). The distinct pathways that maintain pulmonary epithelial
lineagesmay therefore also influence the biology of lung cancers.btype of nonsmall cell lung cancer. During lung ADCprogres-
umors correlates with poor outcome. The underlying mech-
e poorly understood. Through an integrated approach, we
, as inhibitors of metastatic progression. Downregulation of
tumor differentiation and relapses. GATA6 and HOPX coop-
lating converging transcriptional programs of airway epithe-
strate that perturbation of intrinsic cell lineage pathways is a
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Figure 1. Expression of an Alveolar-like Gene Module Correlates with Lung ADC Patient Outcome
(A) Hierarchical clustering was performed on primary ADCs from the NCI Director’s Challenge Cohort (DCC; n = 442) based on 249 genes that mark AT2 cell
differentiation and airway homeostasis. The heatmap represents tumors clustered into ‘‘DASC-like’’ or ‘‘alveolar-like’’ subsets.
(B) Gene set enrichment analysis (GSEA) showing the similarities between activated genes in ‘‘DASC-like’’ tumors and distal airway stem cells. NES, normalized
enrichment score.
(C) Frequency of poorly, moderately, or well-differentiated stage I tumors within the ‘‘alveolar-like’’ and ‘‘DASC-like’’ groups.
(D) Normalized log2 expression values of epithelial lineagemarkers in stage I ADCs in DCC tumors. Data presented as a Box-whisker plot (5%–95%). The p values
were calculated by Student’s t test with Bonferroni correction. ns, not significant.
(E) Kaplan-Meier curves for the overall survival of DCC patients classified as in (A). The p values were calculated by log rank test.
(F) NSCLCs from the DukeMedical Center were classified as in (A), and survival is plotted for patients with ADC (green and red curves) versus SCC (black and gray
curves). The p values were calculated by log rank test.
See also Figure S1 and Table S1.
Cancer Cell
Lineage Selective Genes in Lung Cancer MetastasisLung ADC is the most frequently diagnosed thoracic malig-
nancy with a high incidence of metastasis and death (Jemal
et al., 2008). To date, many somaticmutations have been discov-
ered in ADCs, with most being predicted oncogenes (Weir et al.,
2007). Several of these mutations are required for the survival of
well-differentiated cancer cells (Singh et al., 2009; Weir et al.,
2007), which can maintain features of alveolar cells (Hecht
et al., 2001). However, during its clinical course, ADC can also
adopt mixed histological and molecular features of squamous
(Wilkerson et al., 2012) and small cell lung cancers (Alam et al.,
2010), which expressmarkers of basal and neuroendocrine cells,
respectively. The appearance of these alternate lineage traits in
ADCs correlates with therapeutic resistance and poor prognosis,
but their underlying causes and influence on metastasis are
unknown.
Primary lung ADCs are biologically heterogeneous and can be
classified by gene expression profiles (Bhattacharjee et al., 2001;
Wilkerson et al., 2012). Given that ADCs arise in the peripheral
lungs, we hypothesized that a comprehensive analysis of genes
involved in airway and/or alveolar differentiation would reveal
mechanisms of ADC heterogeneity and metastasis. In the pre-
sent study, we examined the molecular relationship between726 Cancer Cell 23, 725–738, June 10, 2013 ª2013 Elsevier Inc.cell differentiation states, lung cancer subtypes, and clinical
outcome, to discover a role for lineage-restricted genes in the
pathogenesis of lung ADC.
RESULTS
Identification of an Alveolar-like Differentiation Gene
Module that Correlates with Lung ADC Outcome
To stratify ADCs into biologically informative subsets, we first
compiled transcriptomic alterations observed in activated
embryonic stem cells (Ben-Porath et al., 2008; Wong et al.,
2008), human AT2 cells differentiated from embryonic cells
(Ballard et al., 2010; Gonzales et al., 2002), and mouse models
of airway homeostasis (Xu et al., 2010). These gene expression
patterns were analyzed across multiple cohorts of resected
primary human ADCs (Figure S1A available online). From
this, we identified a module of 249 airway and/or alveolar-
like differentiation genes (Table S1) that stratifies two distinc-
tive molecular classes of ADCs (Figure 1A). We refer to these
groups here as the ‘‘distal airway stem cell (DASC)-like’’ subtype
and the ‘‘alveolar-like’’ subtype, based on a number of
observations.
Cancer Cell
Lineage Selective Genes in Lung Cancer MetastasisFirst, according to the recent characterization of human
airway stem or progenitor cells (Kumar et al., 2011), the molec-
ular features of ‘‘DASC-like’’ tumors are more akin to undifferen-
tiated distal airway stem cells (DASCs) as opposed to proximal
tracheal airway stem cells (TASCs) (Figures 1B and S1B). Sec-
ond, many poorly differentiated ADCs are grouped in the
DASC-like subset, while most well-differentiated tumors classify
as alveolar-like (Figure 1C). Notably, even within early-stage
tumors, the expression of prototypical AT2 lineage markers
were decreased in the DASC-like tumors, including surfactant
proteins encoded by SFTPB-D (Morrisey and Hogan, 2010)
and the protease that cleaves their immature form encoded by
PGC (Gerson et al., 2008) (Figures 1D and S1C). These tumors
also expressed lower levels of SCGB1A1 (Figure S1C), which
is expressed in cells of the proximal lung and bronchioalveolar
junctions. However, the expression of the marker of multipotent
lung progenitors ID2 (Rawlins et al., 2009) and the epithelial
marker CDH1 (E-cadherin) were unchanged (Figure 1D). As
such, the bulk of DASC-like tumors is partially dedifferentiated
relative to known airway lineages but retains features of an
epithelial cell type. In DASC-like tumors, the expression of
WNT inhibitory factor 1 (WIF1), an antagonist of the canonical
WNT pathway (Clevers, 2006), was suppressed (Figure S1C),
consistent with hyperactive WNT/TCF signaling being a medi-
ator of lung ADC progression and metastasis (Nguyen et al.,
2009; Pacheco-Pinedo et al., 2011). Patients harboring DASC-
like tumors tended to have decreased five-year survival rates
and increased incidence of metastasis or recurrence (Figures
1E and 1F; Figures S1D and S1E, red versus green subsets).
These observations were conserved across seven independent
ADC data sets (664 tumors) and are significant based on random
permutation tests (p < 0.0001). However, in two SCC cohorts,
this gene module was not linked to outcome (Figures 1F and
S1E, gray versus black subsets). The transcriptional control of
alveolar differentiation in NSCLCs is therefore preferentially
associated with ADC metastatic progression.
Expression of the Lineage Transcription Factors GATA6
and HOPX Is Linked to Metastatic Competence in Lung
ADC
The transcriptome of DASC-like ADCs may reflect the activity of
a molecular pathway linked to alveolar differentiation. Frequent
ADC mutations include the mutants EGFR, KRAS, STK11, and
TP53. However, the presence of these mutations by themselves
did not correlate with the lineage classification (Figure S2A). To
identify mediators of this putative metastasis program, we
focused on TF expression and activity, because several classes
of TFs are known to balance pluripotency and pulmonary cell
fate (Morrisey and Hogan, 2010). Global TF activity can be
inferred from the relative enrichment of known TF binding motifs
within the promoters of a given gene set. We cross-validated two
independent algorithms for TF cis motif analysis across four
major ADC cohorts. Motifs for 57 TFs were enriched in the tran-
scriptome of DASC-like ADCs (Figure 2A; Table S2). The over-
represented motifs were mainly for E2F family members and
MYC (Figure 2A; orange), consistent with previous reports
showing activation of their target genes in aggressive cancers
(Rhodes et al., 2005; Sinha et al., 2008). In contrast, the under-
represented motifs were targets for less-well-characterizedTFs that are tissue specific. This included several conserved
GATA family binding sites (Figure 2A; blue).
GATAs can either activate or repress transcription and have
redundant or specific target genes depending on the biological
context (Molkentin, 2000). Of the six known family members,
GATA6 is essential for endodermal differentiation and distal
airway homeostasis (Keijzer et al., 2001; Liu et al., 2002a; Yang
et al., 2002). It maintains proper alveolar gene expression in
cooperation with other known lineage TFs, including HOPX
(Yin et al., 2006) and NKX2-1 (Liu et al., 2002b; Zhang et al.,
2007). Interestingly, GATA6, HOPX, and NKX2-1 were part of
the lineage signature (Table S1), and their expression was gener-
ally reduced in poor prognosis tumors (Figures 2B and S2B). The
expression of otherGATAs varied less across human ADCs (Fig-
ure S2B). HOPX lacks a DNA binding domain (Chen et al., 2002;
Shin et al., 2002), explaining why it did not score in our cis motif
analysis. NKX2-1 targets annotated in this analysis were not
broadly over- or underrepresented. Based on recent ADC rese-
quencing efforts, copy number variations and somatic mutations
in GATA6 and HOPX were rare (Figure S2C), suggesting that
perturbation of these TFs occurs at the level of their expression.
To further ascertain the correlation of these lineage TFs with
metastasis, we compared their expression in several models of
ADC metastatic progression. ADC metastasis can be generated
via in vivo selection of metastatic cell subpopulations (BrM3
cells) from the human lung ADC cell lines H2030 and PC9, which
carry KRAS and EGFR mutations, respectively. Following trans-
plantation in mice, BrM3 cells have enhanced metastatic predi-
lections when compared to their parental cells (Nguyen et al.,
2009). Messenger RNA (mRNA) levels of GATA members were
generally reduced in BrM3 cells (Figure S2D). Suppression of
GATA6 and known HOPX isoforms was not entirely associated
with DNA methylation (Figures S2E and S2F). Still, GATA6
expression was notably decreased in the metastatic H2030-
BrM3 cells as compared to their indolent parental cells, whereas
HOPX was undetectable in both H2030 populations (Figures 2C
and 2D). GATA6 expression varied less in the PC9-BrM3 sub-
population, but these cells express significantly lower levels of
HOPX (Figures 2C and 2D). Although NKX2-1 is a prognostic
marker (Barletta et al., 2009), its inhibition may occur indepen-
dently because its expression was already low to undetectable
in these human cells and did not further correlate with their met-
astatic predilection (Figure S2G). Murine ADC cell lines have
been isolated from genetically engineered mice with NSCLC
initiated by Kras and p53 mutations (Winslow et al., 2011). In
this model, aggressive primary tumor cells (TMet) with low
Nkx2-1 and their clonally derived metastatic cells (Met) also
tend to express decreased levels of Gata6 and Hopx as
compared to cells fromnonmetastatic ADCs (TnonMet) (Figure 2E).
Altogether, the suppression of alveolar lineage TFs in a subset of
primary tumors is linked to the selection of metastatic ADCs. In
particular, low levels of both GATA6 and HOPX in ADCs corre-
lated with poor outcome, even when accounting for patient
smoking status, sex, and tumor stage (Figure 2F).
GATA6 and HOPX Limit Multiorgan Metastasis
To test the functions of GATA6 and HOPX in human ADC cells,
we reduced their levels via inducible small hairpin RNAs
(shRNAs) in the less aggressive H2030 and PC9 parental cells.Cancer Cell 23, 725–738, June 10, 2013 ª2013 Elsevier Inc. 727
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Figure 2. TF Activity and Expression in DASC-like Tumors and Metastatic ADC Cells
(A) Annotated cis TF motifs from TRANSFAC database were computed for enrichment in the transcriptome of ADC subsets. The heatmap depicts motifs that are
significantly over- (orange) or underrepresented (blue) in ‘‘DASC-like’’ ADCs from four independent patient cohorts. Enrichment scores were reported based
on -log10(p value) from GSEA.
(B) Normalized log2 values for GATA6 and HOPX expression in DCC. The p values were calculated by Student’s t test with Bonferroni correction.
(C) GATA6 and HOPX were measured in the indicated cell lines via quantitative real-time PCR. U.D., undetected. Bar charts represent the mean ± SEM.
(D) Western blot of GATA6 and HOPX in the indicated cell lines.
(E) Normalized log2 values ofGata6 andHopx expression in nonmetastatic primary (TnonMet; n = 7), metastatic primary (Tmet; n = 7) andmetastases (Met; n = 9) cell
lines derived from a KrasLSL-G12D/+;p53flox/flox lung ADC mouse model. The p values were calculated by Student’s t test with Bonferroni correction.
(F) Survival of DCC patients based on the median expression ofGATA6 and HOPX in their primary tumors. The p values were calculated by log rank test. Hazard
ratio (HR) and confidence interval were calculated using patient sex, smoking status, and tumor stage as covariates.
See also Figure S2 and Table S2.
Cancer Cell
Lineage Selective Genes in Lung Cancer MetastasisWe confirmed that doxycycline (DOX) treatment caused efficient
and sustained induction of hairpin expression in disseminated
tumor cells in an immunocompromised mouse model (Fig-
ure S3A). Our functional results were validated using indepen-
dent hairpins (shRNAs a and b) and small interfering RNA
(siRNAs) against each gene where indicated.
Based on the alveolar-like signature, H2030 cells were less
differentiated than PC9 cells (data not shown) and already
express low amounts of HOPX (see Figure 2D). Accordingly,
we reduced GATA6 in parental H2030 cells (Figure 3A) and
injected them at different dilutions into the arterial circulation of
mice that were either treated with DOX or control feed. Knock-
down of GATA6 in parental H2030 cells was sufficient to
enhance their metastatic capabilities (Figure 3B) but had only a
modest effect on subcutaneous tumorigenesis (Figure S3B).
On the other hand, overexpression of GATA6 and/or HOPX in
the highly metastatic H2030-BrM3 cells, which express low728 Cancer Cell 23, 725–738, June 10, 2013 ª2013 Elsevier Inc.endogenous levels of both TFs (Figure S3C), inhibited their met-
astatic potential (Figure 3C). We then decreased the expression
of GATA6 and HOPX individually or in combination in the more
differentiated PC9 cells, which express high levels of both TFs,
and achieved 71% knockdown of GATA6 and over 90% knock-
down ofHOPX (Figures 3D and S3D). Although HOPX is a down-
stream target of GATA6 in AT2 cells (Yin et al., 2006), their
expressions were not interdependent in PC9 cells (Figure 3D).
Knockdown of GATA6, together with HOPX, enhanced the pro-
portion of animals with high metastatic burden, which could be
rescued by ectopic expression of shRNA-resistant complemen-
tary DNAs (cDNAs) (Figure 3E; Figures S3E and S3F). When
injected into circulation at lower cell numbers, GATA6 and
HOPX knockdown increased the incidence of multiorgan metas-
tasis (Figure 3F). Metastases were confirmed in brain, bone, and
lungs (Figure 3G). GATA6 and HOPX did not significantly alter
the proportion of PC9 cells expressing CD133 (Figure S3G), a
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(A) H2030 cells stably expressing two separate doxycycline (DOX)-inducible shRNAs, (a) or (b), againstGATA6were cultured in the absence or presence of DOX.
GATA6 level was measured by quantitative real-time PCR.
(B) H2030 cells from (A) were injected at indicated cell numbers into the arterial circulation of mice fed with regular (DOX) or DOX (+DOX) diet. Metastatic burden
was measured by bioluminescent imaging. The bar chart shows the whole-body bioluminescent units (BLU) collected at day 36 [shGATA6(a)] or day 40
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Cancer Cell
Lineage Selective Genes in Lung Cancer Metastasisputative tumor-initiating cell marker, and did not affect tumori-
genic potential (Figure 3H). We conclude that these TFs can
cooperatively limit themetastatic competence of ADC cells inde-
pendent of tumor growth.
GATA6 and HOPX Constrain Invasogenic Outgrowth
Given the metastasis inhibitory functions of GATA6 and HOPX
in vivo, we ascertained the cell biological mechanism of their
action. Under two-dimensional (2D) growing conditions, knock-
down of GATA6 in H2030 cells did not affect cell survival even
when deprived of growth factors, whereas KRAS knockdown
caused a significant decrease in their viability (Figures 4A and
S4A). In PC9 cells, loss of GATA6 and/or HOPX did not alter
cell growth (Figure 4B), whereas reduction of GATA2 and
EGFR inhibited cell viability as previously reported (Figure 4C;
Figures S4B and S4C) (Kumar et al., 2012; Rothenberg et al.,
2008). Thus, in these ADC cells, GATA6 and HOPX are not line-
age survival genes.
To study metastatic cellular phenotypes in the more differenti-
ated PC9 cells, we optimized a three-dimensional (3D) culture
model for tumor organoid formation in extracellular matrix.
Under these conditions, PC9 parental cells formed solid orga-
noids (Figure 5A; inset). Suppression of HOPX caused an
outgrowth of these organoids, and this effect was enhanced in
combination with GATA6 knockdown (Figures 5A and 5B; Fig-
ures S5A and S5B). GATA6 and/or HOPX knockdown did not
alter the overall number of organoids (Figure 5C, top), even
when single cells were seeded (Figure S5C), but significantly
changed the morphologies of these organoids. Extending on
prior characterization (Kenny et al., 2007), we termed these
mass, grape-like or expansive organoids. Mass organoids main-
tained spherical appearance, whereas grape-like and expansive
organoids were disorganized. The expansive organoids were the
largest multicellular structures, and they correlated with an
increase in PC9 cell outgrowth. Knockdown of GATA6 or
HOPX augmented the proportion of grape-like organoids (Fig-
ure 5C, teal). HOPX suppression also moderately increased
the amount of expansive organoids (Figure 5C, red). Double
GATA6 and HOPX knockdown greatly increased the proportion
of expansive organoids (Figure 5C), which was prevented by
rescue of GATA6 and HOPX expression (Figure S5D). Moreover,
GATA6 and HOPX reinduction in pre-established organoids by
DOX withdrawal delayed their expansion (Figure 5D).
The morphology of the grape-like and expansive organoids
suggests that they are highly invasive. To test this directly, we
dissociated cells from the organoids and compared their invasive[shGATA6(b)] and normalized to day 0. Right: representative images of mice inject
the Mann-Whitney test.
(C) H2030-BrM3 cells overexpressingGATA6,HOPX, or both were injected (53 10
The p values were calculated using the Mann-Whitney test.
(D) GATA6 and HOPX levels in PC9 cells expressing the indicated shRNAs. shCo
(E) PC9 cells expressing the indicated shRNAs were injected intracardially into D
burden at day 48. Bottom: representative images of mice with metastases. The
(F) Kaplan-Meier curve showing the metastasis-free survival of mice inoculate
PC9-shGATA6/shHOPX(b) cells that coexpress GATA6 and HOPX cDNAs (+Res
(G) Hematoxylin and eosin staining of metastases in the (a) brain, (b) bone, and (
(H) Volumes of subcutaneous tumors formed by PC9-shGATA6/shHOPX(a) cells
significant.
Bar charts represent the mean ± SEM. See also Figure S3.
730 Cancer Cell 23, 725–738, June 10, 2013 ª2013 Elsevier Inc.potential through Matrigel. Cells from the grape-like and/or
expansive organoids were more invasive than those from the
masses (Figure 5E). GATA6 and HOPX also cooperatively limit
the invasion of PC9 cells cultured directly from monolayer (Fig-
ure 5F). The effect of double knockdown was consistent across
four additional ADC cell lines that express high levels of these
TFs and encompass different genetic backgrounds and tumor
stages (Figures 5G and S5E). In contrast, invasion was not
affected by knockdown in two high GATA6/HOPX expressing
non-ADC cell lines (1 SCC and 1 LCC) that we tested (Figures
S5F and S5G). GATA6 reduction was sufficient to promote inva-
sion of the parental H2030 cells (Figure 5G, yellow), consistent
with low levels of HOPX in these ADC cells. This effect was
partially rescued by re-expression of HOPX (Figures S5H and
S5I), confirming its cooperativity with GATA6. Restoration of
GATA6 and HOPX in the metastatic H2030-BrM3 ADC subpop-
ulation inhibited its invasion, whereas overexpression of these
TFs in the low GATA6/HOPX-expressing SCC cell line H520 did
not alter itsmodest baseline invasiveness (Figures S5J and S5K).
Activation of Specific Proinvasive Pathways following
GATA6 and HOPX Reduction
Having defined a cellular function for GATA6 and HOPX in lung
ADC cells, we examined if these TFs affect pathways reported
to mediate lung cancer invasion (Carretero et al., 2010; Nguyen
et al., 2009; Roman et al., 2010; Saito et al., 2009). We analyzed
PC9 cells with GATA6 and/or HOPX knockdown because the
greatest phenotypic alterations were observed in this model.
Surprisingly, the levels of epithelial-mesenchymal transition
(EMT) markers, ZEB1/2, TWIST1, E-cadherin, and vimentin,
were not affected (Figures 6A and S6A). Activation of the canon-
ical WNT pathway was only marginally regulated downstream of
these TFs (Figures 6B and S6B). On the other hand, reduction of
GATA6 andHOPX cooperatively increased Src activation but not
focal adhesion kinase (FAK) (Figure 6C). Finally, we examined the
steady-state levels of several integrin subunits and found that
GATA6 and/or HOPX knockdown led to a marked increase in
integrin a5 but did not consistently affect others (Figure 6C;
data not shown). Thus, GATA6 and HOPX can repress Src activ-
ity and integrin a5 expression in poorly metastatic cells.
GATA6 and HOPX Regulate a Set of Common Genes
Involved in Epithelial Differentiation and Metastasis
To comprehensively understand howGATA6 and HOPX link line-
age fate to metastatic competence, we identified their down-
stream target genes using genome-wide RNA sequencing.ed with H2030-shGATA6(a) cells on day 36. The p values were calculated using
4 cells/mouse) as in (B). The scatterplot shows themetastatic burden at day 42.
n, a control shRNA.
OX-treated mice (5 3 104 cells/mouse). The scatterplot shows the metastatic
p values were calculated using the Mann-Whitney test.
d with 2.5 3 104 PC9-shGATA6/shHOPX(b) cells as in (B) or injected with
cue). The p values were calculated using the log rank test.
c) lung of mice harvested from (E). Scale bars, 100 mm.
. Mean ± SEM; the p values were calculated using the Student’s t test. ns, not
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Figure 4. GATA6 and HOPX Do Not Affect Tumor Cell Survival
(A) H2030 cells with the indicated shRNAs were cultured in media containing
0.2% fetal bovine serum (FBS). Cell viability was measured at 72 hr after DOX
treatment.
(B) The viability of PC9 cells with the indicated shRNAs wasmeasured inmedia
supplemented with 10% or 0.2% FBS as in (A).
(C) The indicated PC9 cell lines were transfected with siRNA targeting GATA2
(siGATA2). Cell viability was measured in 0.2% FBS at day 5 posttransfection.
Bar charts represent the mean ± SEM. See also Figure S4.
Cancer Cell
Lineage Selective Genes in Lung Cancer MetastasisKnockdown of both TFs in PC9 cells caused transcriptomic
alterations that resemble those of human DASC-like tumors (Fig-
ure 7A, orange labels). These changes also inversely correlate
with the transcriptome of AT2 cells differentiated in vitro and
broadly resemble those of DASCs, but not TASCs (Figure S7A).
To determine if the perturbation of these TFs contributes to rele-vant molecular and histopathological classes of human ADCs,
we examined the relationship between GATA6/HOPX-regulated
genes and three major ADC subgroups, including bronchioid,
magnoid, and squamoid cancers (Wilkerson et al., 2012). The
gene expression profiles of GATA6/HOPX knockdown cells
correlated most with the squamoid subtype (Figure 7A, cyan
labels), which includes highly invasive tumors with mixed
adenosquamous features (Wilkerson et al., 2012).
By filtering the list of coding transcripts based on genes simi-
larly expressed in human tumors, we identified 426 relevant
mRNAs that were differentially regulated by GATA6/HOPX (Fig-
ure 7B; Table S3). We confirmed that many of these genes
were redundantly or cooperatively modulated by GATA6 and
HOPX (Figure 7B, gray and red rectangles), whereas an addi-
tional gene set was only altered by HOPX (Figure 7B, blue
rectangles). The alveolar markers SFTPD and PGC were down-
regulated after reduction of these TFs (Figures 7C and S7B).
Surprisingly, the loss of AT2 identity in tumor cells was accompa-
nied by an increase in the expression of cytokeratins 6A (KRT6A)
and 6B (KRT6B) (Figures 7C and S7B), which are normally
expressed in basal cells and putative DASCs (Kumar et al.,
2011). The expression of secretogranin II (SCG2), a marker of
neuroendocrine cells (Feldman and Eiden, 2003), was also acti-
vated. Consistent with an epithelial lineage switch controlled by
these TFs, GATA6/HOPX expression significantly correlated
with AT2 markers and inversely correlated with KRT6A/B levels
in a proportion of resected human ADCs (Figure S7C).
We also identified a number of target genes that are known
mediators of metastatic colonization (Figures 7D and S7B). For
instance, reduction of GATA6 and/or HOPX led to increased
expression of IL1B, IL11, and EREG, which encode for
secreted factors associated with organotropic metastasis (Bos
et al., 2009; Gupta et al., 2007; Kang et al., 2003). Vascular
and ECM remodeling genes (VEGFA and PLAU) that promote
metastatic progression (Blanco et al., 2012; Weis et al., 2004)
were also activated. Some of the described transcriptional
changes were observed in other ADC cell lines, with KRT6A/B
induction being the most consistent response (Figures S7D
and S7E). Consequently, inhibition of GATA6 and HOPX may
activate a multigenic program that enhances dissemination as
well as distant organ colonization.
GATA6 and HOPX Lineage Target Genes Control
Malignant Cell Invasion
Given that GATA6/HOPX-regulated genes include markers of
lung differentiation and metastasis, the repression of certain
metastatic functions may be intrinsic to the lineage-specifying
activity of these TFs. Moreover, we found that the formation of
tumor organoids from 2D culture upregulates the expression of
the alveolar-like genes HOPX and PGC but represses KRT6A
expression (Figure 8A). Hence, this organoid system recapitu-
lates extracellular conditions that enforce alveolar fate at the
expense of other lineages. The expression pattern of these
markers was reversed in the invasive organoids after GATA6/
HOPX knockdown (Figure 8A), suggesting that this particular dif-
ferentiation program may directly constrain tumor cell invasion.
To test this possibility, we focused on the function of putative
epithelial lineage markers that were aberrantly activated upon
GATA6 and HOPX repression, including KRT6A, KRT6B (MollCancer Cell 23, 725–738, June 10, 2013 ª2013 Elsevier Inc. 731
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Figure 5. GATA6 and HOPX Constrain Cell Invasion
(A) PC9 cells expressing the indicated shRNAs were cultured in low attachment plates with media containing Matrigel and DOX. Phase contrast images were
captured after 14 days of culture. The inset shows a cross-section of a DAPI-stained organoid. Scale bars, 200 mm (25 mm in insert).
(B) Organoids from (A) were harvested, and cell outgrowth was measured as a function of luciferase activity.
(C) The bar chart shows the percentage of mass (black), grape-like (teal), and expansive (red) organoids. The numbers at the top of graph show the overall
numbers (± SEM) of tumor organoids formed at day 8. Representative images of indicated organoids are shown at right. Scale bars, 100 mm.
(D) After 14 days of 3D culture in the presence of DOX, PC9-shGATA6/shHOPX(b) organoids were replated inMatrigel with (+DOX) or without DOX (off-Dox) for an
additional 18–24 days. Tumor cell growth wasmeasured at days 32 and 38 as in (B). Representative images at day 32 are shown. The red fluorescent protein (RFP)
signal indicates shRNA expression. Scale bars, 200 mm.
(E) At day 14, PC9-shGATA6/shHOPX(b) organoids formed in Matrigel in the presence or absence of DOXwere disaggregated and subjected to invasion assay in
Boyden chambers.
(F) PC9 cells expressing the indicated shRNAs were grown in monolayer with DOX for 5 days and then directly subjected to an invasion assay as in (E).
Quantification was normalized to the invasion of cells expressing shCon.
(G) Invasion of additional ADC lines was determined as in (F).
Bar charts represent the mean ± SEM; the p values were calculated using Student’s t test. See also Figure S5.
Cancer Cell
Lineage Selective Genes in Lung Cancer Metastasiset al., 1982), STEAP1 (Gomes et al., 2012), and GPR87 (Glatt
et al., 2008) (Figure 8A). We successfully inhibited their activation
by shRNA or siRNAs in double GATA6/HOPX knockdown cells
(Figures 8B and S8A; data not shown). Surprisingly, reduction732 Cancer Cell 23, 725–738, June 10, 2013 ª2013 Elsevier Inc.of both KRT6A and KRT6B partially restored the expression of
the alveolar marker PGC (Figure 8B). This partial alveologenic
rescue diminished the induction of several prometastatic genes
(Figure 8B) and integrin a5 expression (Figure 8C). Functionally,
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Figure 6. Src and Integrin a5 Are Sup-
pressed by GATA6 and HOPX
(A–C) PC9 cells with the indicated shRNAs tar-
geting GATA6 and/or HOPX were cultured in
monolayer. After 5 days of DOX treatment, cells
were harvested for western blot analysis for (A)
epithelial (E-cadherin) andmesenchymal (vimentin
and N-cadherin) markers, (B) canonical WNT
signaling pathway components, b-catenin and
LEF1, and (C) Src, FAK, and integrin a5. Lysate
from MDA-MB-231 cells serves as a control for
vimentin.
See also Figure S6.
Cancer Cell
Lineage Selective Genes in Lung Cancer Metastasisreduction of both KRT6A and KRT6B, but not STEAP1 and
GPR87, attenuated the organoid outgrowth initiated by GATA6/
HOPX knockdown (Figures 8D and S8B; data not shown).
KRT6A/B knockdown also diminished the invasion of most of
the ADC lines tested (Figures 8E and 8F), suggesting that airway
lineage markers can directly control pathways of lung cancer
cell invasion. Collectively, our data identify GATA6 and HOPX
as context and lineage-selective inhibitors of metastatic
competence.
DISCUSSION
Lineage Markers and ADC Progression
Although several genomic aberrations are associated with lung
cancer progression, our understanding of the metastatic pro-
cess remains incomplete. Emerging evidence indicates that
the transcriptional pathways that are critical for lungmorphogen-
esis can be disrupted or reused during chronic diseases of the
airways (Whitsett et al., 2011). Differentiation and regeneration
of the lung epithelium is dictated by many cooperating transcrip-
tional effectors. Our integrated approach uncovered a transcrip-
tional network that is preferentially active in committed airway
epithelial cells and is inhibited in a subset of metastatic cancers
arising from the distal lungs. Within this network, we found that
the cooperative action of at least two TFs, GATA6 and HOPX,
links the molecular determinants of alveologenesis to metastatic
competence in the lung ADC subtype.
Lung ADCs can arise from AT2 cells, and expression of alve-
olar markers is employed to discriminate lung ADCs from other
thoracic malignancies. However, epithelial transdifferentiation
may occur in ADCs. Notably, some ADCs express markers of
squamous (Wilkerson et al., 2012) or small cell lung cancers
(Alam et al., 2010), and distinct histological subgroups correlate
with relapse (Travis et al., 2011). These observations imply that
the cellular composition and/ormolecular determinants of airway
specification vary during ADC progression and can influence
clinical outcome. We found that a gene signature modulated in
part by GATA6 and HOPX repression correlates with classifiers
of poor prognosis. Importantly, this lineage classification is asso-
ciated with metastasis in patients with ADC, but not SCC.Cancer Cell 23, 725–7GATA6 and HOPX as Inhibitors
of Metastasis
We discovered that GATA6 and HOPX
expression and activity are reduced in asubset of high-grade ADCs and metastatic cells. Suppression
of both TFs can enhance the invasion of lung ADC cell lines
with different mutations, but this did not have the same effect
in SCC cell lines tested here. Although GATA6with HOPX prefer-
entially limits ADC metastatic competence, it remains to be
determined under which genetic/epigenetic context(s) this activ-
ity is enforced and whether these TFs have alternate roles in
other NSCLCs with particular molecular aberrations or tumor
stages. In various cancers, GATA members may promote (Bela-
guli et al., 2010; Collisson et al., 2011; Lin et al., 2012; Yang et al.,
2011) or inhibit (Cai et al., 2009; Kouros-Mehr et al., 2008; Lind-
holm et al., 2009) cancer. This is analogous to another important
TF in NSCLC, NKX2-1, which can function as an oncogene (Weir
et al., 2007) or tumor suppressor (Maeda et al., 2012; Snyder
et al., 2013; Winslow et al., 2011). HOPX levels inversely corre-
late with tumorigenesis (Chen et al., 2007; Ooki et al., 2010),
but its mechanism of action has been unknown. The biological
activity of such lineage factors likely depends on their integration
within a TF network that is unique to particular cellular contexts.
The lung buds are derived from the endoderm, which is spec-
ified byGATA6 (Morrisey andHogan, 2010). GATA6 also restricts
the expansion of progenitor cells in the adult airways, where it is
abundantly expressed (Morrisey et al., 1996; Zhang et al., 2008).
To maintain AT2 homeostasis, at least two other TFs, NKX2-1
and HOPX, can synergize with or are regulated by GATA6 (Liu
et al., 2002b; Yin et al., 2006; Zhang et al., 2007). Our data, along
with the aforementioned studies, support a model in which sup-
pression of this TF node and divergent alveologenesis directly
influence ADC progression. These findings further suggest that
inhibition of HOPX together with GATA6 in transformed ADC
cells is an important determinant of invasion andmetastasis initi-
ation. This does not inherently exclude the possibility that metas-
tasis could also originate from progenitors with low GATA6 and
HOPX activity. Although we found that GATA6 and HOPX could
further limit ADC metastatic colonization, overt metastasis likely
requires multiple physiological or molecular perturbations and
other lineage genes may be involved. Additional insight into the
diverse pathogenesis of NSCLCs will be uncovered by studying
the timing, cellular context, and mechanisms by which combina-
tions of lineage TFs are deregulated.38, June 10, 2013 ª2013 Elsevier Inc. 733
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Figure 7. Common Regulation of Airway Differentiation and Metastasis Gene Sets
(A) Pearson correlation coefficients were calculated for each DCC tumor by comparing its mRNA transcriptome to the shGATA6/shHOPX knockdown signature
generated by RNA sequencing of PC9 cells. DCC tumors were ordered from lowest to highest correlation with shGATA6/shHOPX knockdown cells (top). His-
tological andmolecular subtypes are annotated in the middle and bottom rows for comparisons. DASC-like samples have a higher correlation withGATA6/HOPX
knockdown cells than with alveolar-like tumors (middle row; p value by Student’s t test). Squamoid andmagnoid tumors have a higher correlation than bronchioid
tumors (bottom row; p value by ANOVA).
(B) Left: the heatmap depicts 426 genes that are commonly upregulated (red) or downregulated (green) in shGATA6/shHOPX knockdown cells and DCC tumors.
Right: top 50 up- and downregulated genes. Genes that were validated by quantitative real-time PCR are denoted with rectangles. Blue, controlled by HOPX;
gray, redundantly controlled by GATA6 and HOPX; red, cooperatively controlled by GATA6 and HOPX; *, confirmation of HOPX and GATA6 knockdown.
(C) Quantitative real-time PCR measurement of alveolar (SFTPD and PGC), basal (KRT6A and KRT6B), and neuroendocrine (SCG2) marker expression in DOX-
treated PC9 cells with the indicated shRNAs.
(D) Expression of known metastasis genes as in (C).
For quantitative real-time PCR data, expression was normalized to PC9-shCon cells and presented as the mean ± SEM. See also Figure S7 and Table S3.
Cancer Cell
Lineage Selective Genes in Lung Cancer MetastasisGATA6 and HOPX Directly Link Metastatic Invasion
to Airway Cell Fate
GATA6 and HOPX modulated the transcription of overlap-
ping genes, some of which were cooperatively activated or734 Cancer Cell 23, 725–738, June 10, 2013 ª2013 Elsevier Inc.repressed. Because HOPX lacks a DNA binding domain, it
must interact with other sequence-specific TFs to account
for its effects. Certain GATA6/HOPX-regulated genes encode
for cellular functions that link airway epithelial differentiation
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Figure 8. GATA6 and HOPX Link Epithelial Identity with Invasion through KRT6A and KRT6B
(A) PC9 cells with the indicated shRNAswere cultured inmonolayer (2D) orMatrigel suspension (3D) for 5 days as in Figure 5. Expression of the indicated epithelial
markers was detected by quantitative real-time PCR.
(B) PC9-shGATA6/shHOPX(b) knockdown cells were super-infected with lentiviruses encoding shCon or shRNAs against KRT6A and KRT6B. Expression of the
indicated GATA6/HOPX target genes upon KRT6A/B suppression was detected as in (A).
(C) Western blot showing integrin a5 protein levels in the indicated cell lines.
(D) PC9-shGATA6/shHOPX(b) cells were transfected with the indicated siRNAs and cultured in 3D. Tumor cell outgrowth was quantified and representative
images captured at day 10. Scale bar, 200 mm.
(E) PC9-shGATA6/shHOPX(b) cells were transfected with a control siRNA (siCon) or siRNAs against KRT6A and KRT6B. At 48 hr posttransfection, cells were
subjected to an invasion assay.
(F) Invasion assay was performed using indicated ADC lines with the indicated shRNAs/siRNAs.
Bar charts represent the mean ± SEM; p values were calculated using Student’s t test. See also Figure S8.
Cancer Cell
Lineage Selective Genes in Lung Cancer Metastasisto metastasis. Indeed, suppression of these TFs in ADC
cells decreased AT2 differentiation. This was not sufficient
to induce EMT but caused transformed cells to display charac-
teristics of basal epithelial cells, including KRT6A/B expres-
sion. Concomitantly, these TFs inhibited proinvasive pathways,
such as Src activity and integrin a5 induction, while alsocontrolling known metastasis genes. Surprisingly, KRT6A/B
themselves partially mediated alveolar gene expression and
ADC cell invasion. KRT6A/B are activated in epithelial tissue
during wound healing (Wojcik et al., 2000) and in putative stem
cells of the distal lung following infections (Kumar et al.,
2011). Hence, this switch in lineage markers may represent aCancer Cell 23, 725–738, June 10, 2013 ª2013 Elsevier Inc. 735
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Lineage Selective Genes in Lung Cancer Metastasistransdifferentiating or dedifferentiating event, enabling aggres-
sive ADC cells to adopt traits normally required for airway
regeneration.
Our study highlights the distinct mechanisms of metastatic
competence in different types of lung cancers. In particular, we
have demonstrated that the TFs, GATA6 and HOPX, can inhibit
metastasis in the lung ADC subtype. These factors and their
target genes directly link programs of airway specification to
the pathogenesis of NSCLC. Consequently, certain facets of
this lineage pathway may be explored to more effectively treat
patients with metastatic lung cancers.
EXPERIMENTAL PROCEDURES
Additional details about the experimental procedures are provided in the
Supplemental Experimental Procedures.
Cell Culture, Viability, and Invasion Assays
Cell lines were cultured as recommended by the American Type Culture
Collection (ATCC). Cell viability and invasion were assayed as previously
mentioned (Nguyen et al., 2009). For 3D outgrowth, cells were grown in media
with 5% Matrigel in ultra-low attachment plates (Corning, Tewksbury, MA,
USA) at 37C for 8–14 days. Organoids were categorized as previously
described (Kenny et al., 2007). Expansive organoids are a subset of
grape-like organoids with diameter >200 mm. To quantify outgrowth,
cells stably expressing firefly luciferase were harvested, and luciferase
activity was measured by Dual-Luciferase Reporter Assay (Promega,
Madison, WI).
Gene Knockdown, Quantitative Real-Time PCR, and Western Blot
shRNA sequences, inducible lentiviral vectors, primers, and antibodies are
listed in the Supplemental Experimental Procedures.
Animal Studies
Studies using athymic nu/nu male mice (NCI) aged between 5–7 weeks were
conducted in compliance with U.S. guidelines for the care and use of labora-
tory animals andwere approved by the Institutional Animal Care andUseCom-
mittee of Yale University. DOX was administered in chow (625 mg/kg). An IVIS
Spectrum was used for bioluminescence imaging.
Microarray Data Analysis
Data sets for primary lung cancers, AT2/airway genes, and airway stem cells,
as well as derivation of an ‘‘alveolar-like’’ signature, are listed in the Supple-
mental Experimental Procedures and Table S1. Differential gene expression
and hierarchical clustering were performed in Partek and R.
RNA Sequencing
RNA sampleswere sequenced on a HiSeq 2000 (Illumina, San Diego, CA, USA)
and analyzed using Tophat and EdgeR.
Statistical Analysis
Experimental data are presented as mean ± SEM. The p values for in vitro data
and tumor volume are calculated by two-tailed Student’s t test. Survival curves
and metastatic burden were analyzed by log rank test and Mann-Whitney test,
respectively.
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